David Frawley

Plus aucun poste en cours

Health Technology

Consumer Services

Profil

David Frawley worked as EVP & Chief Commercial Officer at Sumitomo Pharma America, Inc. and as SVP-GMSA, Customer Excellence & Operations at Karyopharm Therapeutics, Inc. He holds an MBA from the University of Bradford and an undergraduate degree from The University of Southampton.

Anciens postes connus de David Frawley

Sociétés	Poste	Fin
Sumitomo Pharma America, Inc. Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA.	Corporate Officer/Principal	01/01/2019
KARYOPHARM THERAPEUTICS INC.	Corporate Officer/Principal	-

Voir l'expérience en détail de David Frawley

Formation de David Frawley

University of Bradford	Masters Business Admin
The University of Southampton	Undergraduate Degree

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées